MedTrace Logo

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

NCT01611766 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2021-06-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.

Conditions

Interventions

PROCEDURE

Secondary Cytoreductive Surgery

Complete Cytoreduction

DRUG

Salvage Chemotherapy

6 cycles of postoperative chemotherapy

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Shanghai Gynecologic Oncology Group

    lead OTHER_GOV

Principal Investigators

  • Rongyu Zang, MD,PhD · Shanghai Gynecologic Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-19
Primary Completion
2019-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01611766 on ClinicalTrials.gov